Sign in
CKPT Stock Price, Chart, Stats & News
Checkpoint Therapeutics, Inc.
Save
367.72M
Market cap
–
Current P/E
–
Forward P/E
CKPT chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | -145.88% |
ROE | 1676.13% |
D/E | – |
Interest coverage ratio | – |
CKPT valuation
P/E | – |
P/S | – |
P/B | 0.16x |
P/CF | -0.08x |
P/FCF | -12.23x |
P/OCF | -0.08x |
PEG | 0.00x |
EV multiple | -8.06x |
About
Checkpoint Therapeutics, Inc. is a clinical-stage company specializing in immunotherapy and targeted oncology. Its mission involves discovering, advancing, and bringing to market innovative therapeutic solutions for individuals battling solid tumor cancers. The company's pipeline features several key candidates, including Cosibelimab, a leading fully-human IgG1 monoclonal antibody.
Similar securities
Based on sector and market capitalization
Report issue